MDxHealth spent the second quarter turning a reimbursement shock into a narrower company. After Novitas hit the Resolve urinary-tract franchise with a recoupment claim, management shut the Plano laboratory, parked the subsidiary in an assignment for the benefit of creditors, and pointed the sales force back at prostate cancer. The operating story that remains is a three-test urology menu built around Confirm mdx, GPS mdx, and the newly acquired ExoDx urine assay. Sequential tissue volume recovered after a messy first-quarter integration, and continuing revenue grew versus the year-ago period. The equity debate is no longer whether the company sells useful tests. It is whether a real commercial franchise can outrun a capital structure that already treats common stock as a residual claim.
The tension sits in the mix and the balance sheet rather than in demand. Tissue tests still carry most of the revenue, but ExoDx has pulled mix toward a lower-margin liquid assay and lifted selling and administrative cost. Continuing revenue reached $27 million in the quarter. That print was 16 percent above the year-ago period and about $3 million above the first quarter. Adjusted earnings before interest, taxes, depreciation, and amortization flipped from a small profit a year earlier to a $2 million loss. Cash at mid-year sat at $19 million, thin enough that the September interim report restated substantial doubt about going concern. Management then sold roughly forty-four million new shares at forty-five cents, lifting pro forma cash and lifting the share count to about ninety-five million. Nasdaq has already sent a bid-price deficiency notice and a separate market-value notice.
What the next two quarters resolve is whether tissue acceleration and ExoDx conversion produce the positive adjusted-earnings run-rate management has attached to year-end, or whether earn-out cash, secured-lender interest, and another equity raise arrive first. The listed price around sixty-three cents capitalizes the franchise at a distressed sales multiple after net debt. The bull case needs the prostate menu to grow into the debt. The bear case treats the August placement as the first, not the last, recapitalization.